Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
about
Data mining of the public version of the FDA Adverse Event Reporting SystemSignal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®).Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal.An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital.Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection.Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADREfficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.Drug-drug interactions with imatinib: An observational study.Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol)Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China.Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database.Atropinic (Anticholinergic) Burden in Parkinson's Disease.Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database.Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy.Adverse drug reactions to self-medication: a study in a pharmacovigilance database.Do Parkinson's disease patients disclose their adverse events spontaneously?Psychiatric adverse drug reactions to glucocorticoids in children and adolescents: a much higher risk with elevated doses.Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports.Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database.Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.
P2860
Q30651235-4D536F05-74C8-414F-8D41-058C277D107DQ31056264-0A203960-91ED-4106-B222-5CA691EDC207Q33398329-390A56E6-C6FB-40D1-81A8-6D860F7CA125Q34623753-60453FE8-2D9D-419F-9601-2F1C5C0AD8BEQ35582089-209ECA34-88FB-4AA1-9BEB-11D49CF9CD51Q36088026-F9FD80CE-5E90-4487-9151-D0DD0866A2DEQ36161996-FF611A54-FE99-4C3A-BF7F-E1019BFE2384Q37099049-51B5C0DB-F05E-4DE5-A5C1-6A894DC4DE74Q37264128-7D73A46B-6DFA-48BA-80F5-F72B27AE8796Q37328934-E396E472-2B6F-4635-9012-6919516CE9C0Q37397808-799586CD-F82D-42AD-8C78-2E4602DEBFACQ37889802-F0EE7545-80D8-4579-B1A8-A5026120FDB2Q38019585-77850685-649E-41B9-B8A4-108F0443CA16Q38073712-62C1A898-756F-4E1D-9DD2-D614C71F2726Q38146900-1F56456B-34DD-4F90-BE5A-7FCE479A6164Q38492375-366662F9-56FF-4EE2-910D-EEDA8F43F4BBQ38793600-0D8DE145-75BA-4998-9C04-7FD5845FC0E6Q39652499-8EA37EC3-2790-4EBA-AD23-F801FCA5540DQ39875505-D4C93B7E-14F5-4C56-8B14-52C4BB7C5C8BQ39986375-22ECFD1A-2E40-43C0-8FE8-80FA22C10633Q40690768-6439DBF8-D4AF-4B59-AC03-85EC34BF62E5Q42630468-0B551CEA-F4E7-4FAB-92BB-51F009AEF7D1Q43112707-94EB19A7-6BE5-4573-860A-D84EF5CB1A9FQ43958079-C18348B8-0EF2-47A1-9C51-6DAA59826A2AQ44731914-08B931E8-AF5E-4DF1-B3CD-D25768E85FABQ45353512-2C71A833-AF7F-41CF-9850-2D0F27550AD8Q51136025-E227A5B7-92F3-4FF8-BA5C-9FCD3B9B168A
P2860
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@ast
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@en
type
label
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@ast
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@en
prefLabel
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@ast
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@en
P2093
P50
P1433
P1476
Pharmacovigilance for evaluati ...... ue, organization, and methods.
@en
P2093
Agnès Sommet
Geneviève Durrieu
Haleh Bagheri
Isabelle Lacroix
P304
P356
10.1016/J.JBSPIN.2006.09.002
P577
2006-10-12T00:00:00Z